Loading stock data…
FLGT
$18.50+0.19 (+1.04%)
Market ClosedLast close Jun 9
Fulgent Genetics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fulgent Genetics, Inc. in the Healthcare sector is trading at $18.50. Wall Street consensus targets $18.50 (2 analysts), implying a +0.0% move over the next 12 months. The stock is currently 40% below its 52-week high of $31.04, remaining 15.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$18.50
Potential Downside
0%
Whystock Fair Value$18.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.03%
Volume
Today's trading volume
299,198
Recent News
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments
Fulgent Genetics enters this update cycle with no changes to its price targets, leaving the existing analyst expectations intact for now. Even without new signals on where analysts think the stock could head next, you can still track what this steady stance might mean for your own view of the company. Read on to see how to keep up with the evolving narrative around Fulgent Genetics and where to look as fresh information comes through. Stay updated as the Fair Value for Fulgent Genetics shifts...
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Despite a dip in revenue, Fulgent Genetics Inc (FLGT) focuses on strategic acquisitions and pipeline advancements to bolster future growth.
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Fulgent Genetics, Inc.'s Q1 2026 earnings call
Fulgent Genetics Q1 Earnings Call Highlights
Fulgent Genetics (NASDAQ:FLGT) reported first-quarter 2026 revenue of $71.1 million as the company worked through a planned decline in testing volumes from its largest customer while integrating the recently completed acquisitions of Bako Diagnostics and StrataDX. First-quarter revenue pressured by
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?